ATE303821T1 - Neue vakzinformulierung aus dna-vakzine- inaktiviertem virus - Google Patents

Neue vakzinformulierung aus dna-vakzine- inaktiviertem virus

Info

Publication number
ATE303821T1
ATE303821T1 AT01274060T AT01274060T ATE303821T1 AT E303821 T1 ATE303821 T1 AT E303821T1 AT 01274060 T AT01274060 T AT 01274060T AT 01274060 T AT01274060 T AT 01274060T AT E303821 T1 ATE303821 T1 AT E303821T1
Authority
AT
Austria
Prior art keywords
vaccine
virus
formulation
dna
inactivated virus
Prior art date
Application number
AT01274060T
Other languages
English (en)
Inventor
Narasimhan Rangarajan Pundi
Alwar Srinivasan Villuppanoor
Bowli Gachchi
Biswas Ssitanath Sm Subhabrata
Sreenivasa Reddy Guddeti
Original Assignee
Indian Inst Scient
Indian Immunologicals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Indian Inst Scient, Indian Immunologicals Ltd filed Critical Indian Inst Scient
Application granted granted Critical
Publication of ATE303821T1 publication Critical patent/ATE303821T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT01274060T 2001-02-15 2001-02-15 Neue vakzinformulierung aus dna-vakzine- inaktiviertem virus ATE303821T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IN2001/000018 WO2002078732A1 (en) 2001-02-15 2001-02-15 A noval vaccine formulation consisting of dna vaccine inactivated virus

Publications (1)

Publication Number Publication Date
ATE303821T1 true ATE303821T1 (de) 2005-09-15

Family

ID=11076305

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01274060T ATE303821T1 (de) 2001-02-15 2001-02-15 Neue vakzinformulierung aus dna-vakzine- inaktiviertem virus

Country Status (7)

Country Link
US (1) US20040096462A1 (de)
EP (1) EP1365799B1 (de)
CN (1) CN1245217C (de)
AT (1) ATE303821T1 (de)
CA (1) CA2431938A1 (de)
DE (1) DE60113299T2 (de)
WO (1) WO2002078732A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1593392B1 (de) * 2004-05-07 2011-09-28 Novartis Vaccines and Diagnostics GmbH Tollwut-Impfstoff
EP1844142B1 (de) 2005-01-20 2015-08-12 Nature Technology Corporation Vektoren und verfahren zur genetischen immunisierung
US20060275776A1 (en) * 2005-06-01 2006-12-07 Angelika Banzhoff Rabies vaccine
CN101095950B (zh) * 2006-06-30 2011-01-26 辽宁成大生物股份有限公司 一种稳定的人用狂犬病疫苗冻干制剂及其制备
AU2008262478B9 (en) 2007-05-29 2014-06-19 Aldevron, L.L.C. Vectors and methods for genetic immunization
CN101768206B (zh) * 2008-12-31 2013-05-15 华北制药集团新药研究开发有限责任公司 一种重组人血清白蛋白的纯化方法及其应用
WO2017178945A1 (en) * 2016-04-11 2017-10-19 Biogénesis Bagó Uruguay S.A. Universal vaccine for viral diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5348741A (en) * 1987-02-03 1994-09-20 The United States Of America As Represented By The Department Of Health And Human Services Vector for recombinant poxvirus expressing rabies virus glycoprotein
WO1990000191A1 (en) * 1988-07-01 1990-01-11 The Salk Institute Biotechnology/Industrial Associates, Inc. Production of rabies glycoprotein g and composition therefor
EP0770397B1 (de) * 1995-10-18 2004-04-21 Akzo Nobel N.V. Newcastle-Krankheitsvirus-Kombinationsimpfstoff
EP0817799A1 (de) * 1995-12-21 1998-01-14 SOLVAY (Société Anonyme) Plasmidimpfstoff gegen pseudorabiesvirus
FR2751227B1 (fr) * 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies canines, notamment les pathologies respiratoires et digestives

Also Published As

Publication number Publication date
US20040096462A1 (en) 2004-05-20
CA2431938A1 (en) 2002-10-10
DE60113299D1 (de) 2005-10-13
EP1365799A1 (de) 2003-12-03
CN1494432A (zh) 2004-05-05
WO2002078732A1 (en) 2002-10-10
EP1365799B1 (de) 2005-09-07
WO2002078732A9 (en) 2005-07-07
CN1245217C (zh) 2006-03-15
DE60113299T2 (de) 2006-06-08

Similar Documents

Publication Publication Date Title
WO2020035609A3 (en) Immunogenic compositions and uses thereof
ATE350057T1 (de) Impfstoffzusammesetzung
BR0312173A (pt) Mólecula de cdna, molécula e sequência de cdna recombinante, vetor, processo de preparação de partìculas de vìrus do sarampo infeccioso, composição imunogênica, composição de vacina e vìrus mononegaviral recombinante
WO2007095318A3 (en) Influenza antigens, vaccine compositions, and related methods
DE60226911D1 (de) Entwicklung einer Vakzine zur Prävention von Infektionen mit Filovirus bei Primaten
DK1090033T3 (da) Partikler af HCV-kappeproteiner: Anvendelse til vaccination
AP2002002685A0 (en) Use of flavivirus for the expression of protein epitpoes and development of new live attenuated vaccine virus to immune against flavivirus and other infectious agents
DK1294893T3 (da) Modifikation af hepatitis B-kerneantigen
MXPA02011545A (es) Virus del sindrome respiratorio y reproductor porcino (peesv), vacuna recombinante para el virus de la viruela.
WO2008009652A3 (en) Vaccines for malaria
WO2005013918A3 (en) Compositions, methods and kits relating to poxvirus subunit vaccines
BRPI0707779B8 (pt) antígeno isolado, composição de vacina e método para produção de uma proteína antígeno
BRPI0113155C1 (pt) métodos para produção de uma vacina para hepatite b e de um antígeno de superfície para hepatite b
DK1409692T3 (da) Nye peptider afledt af G-proteinet fra RSV, og anvendelse heraf i en vaccine
BR0312474A (pt) Partìcula viral adjuvante
BR0207988A (pt) Cepas atenuadas vivas de vìrus de prrs
DE60113299D1 (de) Neue vakzinformulierung aus dna-vakzine-inaktiviertem virus
ATE456958T1 (de) Mannose als adjuvant für intranasale vakzine
MY207280A (en) Polyvalent immunogenicity composition for human papillomavirus
WO2005011571A3 (en) Hepatitis virus core proteins as vaccine platforms and methods of use thereof
ATE420658T1 (de) Imidazoquinolinamine als adjuvantien für hiv dna vakzine
DK1423525T3 (da) Rekombinant MVA, der kan eksprimere HCV-strukturantigener
WO2005056051A3 (en) Hepatitis b vaccines and compositions
MX2007002659A (es) Composicion vacunal contra el virus de la hepatitis c.
UY31574A1 (es) Vacunas contra la malaria

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties